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Abstract The mammary gland is one of the most regenerative
organs in the body, with the majority of development occurring
postnatally and in the adult mammal. Formation of the ductal
tree is orchestrated by a specialized structure called the terminal
end bud (TEB). The TEB is responsible for the production of
mature cell types leading to the elongation of the subtending
duct. The TEB is also the regulatory control point for basement
membrane deposition, branching, angiogenesis, and pattern
formation. While the hormonal control of TEB growth is well
characterized, the local regulatory factors are less well under-
stood. Recent studies of pubertal outgrowth and ductal elonga-
tion have yielded surprising details in regards to ongoing pro-
cesses in the TEB. Here we summarize the current understand-
ing of TEB biology, discuss areas of future study, and discuss
the use of the TEB as a model for the study of breast cancer.
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MaSC mammary stem cell
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Overview of Mammary Gland Development
In mammals, development of the mammary gland begins in
the embryo with the formation of bilateral milk lines, or mam-
mary ridges, running anterior to posterior displaced off of the
ventral midline, beginning approximately on embryonic day
10.5 (E10.5) in the mouse [1]. At about E11.5 the lines tran-
sition into five pairs of lens shaped mammary placodes that
mark the ultimate location of each nipple (Fig. 1). The
placodes then evolve to form bulbs of epithelial cells that
eventually invade into the underlying mesenchyme around
E13.5. At this time, the underlying mesenchyme undergoes
differentiation to form the condensed mammary mesenchyme
through which the initial mammary bud must invade [2]. The
mammary mesenchyme plays an important role in the regula-
tion of sexual dimorphism, and is responsible for the
androgen-mediated condensation of mesenchyme around the
primary duct resulting in the elimination of the duct and the
prevention of mammary epithelial growth in males [3].
The mammary buds themselves remain relatively growth
quiescent until about E15.5, at which point hormone-
independent cell proliferation drives bud elongation to form
a mammary sprout. This sprout grows out of the condensed
mammary mesenchyme and invades into the underlying fat
pad precursor mesenchyme to form a solid chord of epithelial
cells called the rudimentary mammary sprout. Subsequently, a
lumen is formed in the sprout [4] and limited branching oc-
curs, giving rise to a rudimentary ductal tree by about E18,
which remains relatively quiescent until puberty at approxi-
mately 3–4 weeks of age (Fig. 1) [5, 6].
At the onset of puberty, increased ovarian production of estro-
gen and pituitary gland production of growth hormone (among
other systemic factors) promote cell division and the formation of
terminal end buds (TEBs). TEBs are bulb-shaped structures
unique to the mammary gland that direct the growth of the ducts
throughout the rest of the fat pad (Fig. 2) [7, 8]. Regular bifurca-
tion and branching during ductal elongation produces the main
ductal system of the mammary tree [8]. Once the TEBs reach the
edges of the fat pad they regress. Further side branching occurs
off of the previously formed ducts during subsequent estrous
cycles in response to progesterone signaling in the adult mammal
but the growth of these side-branches is not driven by TEBs.
Additional development occurs upon pregnancy, when sys-
temic progesterone and prolactin (among others) causes rapid
proliferation of the mammary epithelium to form alveolar buds
(Fig. 1) [9]. During pregnancy, the cells within alveoli undergo
complete differentiation, polarize, and form the secretory alve-
oli capable of producing milk proteins and cytoplasmic lipid
droplets. The precipitous reduction of progesterone in the
Fig. 1 Overview of Mammary
Development. Mammary
placodes are formed on E11.5.
The mammary bud sinks into the
fat pad precursor on E15.5 and
expands to form a rudimentary
duct by E18.5. The gland remains
relatively quiescent until the onset
of puberty, when terminal end
buds are formed and direct ductal
elongation (blow up of pubertal
time point). During pregnancy
alveolar budding and
differentiation take place to give
rise to the milk producing cells.
Adapted from [146]
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context of continued presence of prolactin at parturition acti-
vates the secretory function of these cells characterized by
movement of milk proteins and milk fat globules (membrane-
bound cytoplasmic lipid droplets) into the lumen [10, 11].
Upon weaning, most epithelial cells in the differentiated
alveoli undergo apoptosis and are cleared from the gland by
both macrophages and a subset of surviving mammary epithe-
lial cells [12, 13]. The gland undergoes progressive remodel-
ing back to a virgin-like state through a process collectively
called Binvolution^ (Fig. 1). The process of alveolar differen-
tiation, lactation, and involution can occur repeatedly while
the animal is capable of reproducing, making the mammary
gland one of the most regenerative organs in the body.
Overview of Terminal End Buds across Species
Terminal end buds have been described in rodents (e.g. mice,
rats), as well as in humans and other primates, but not in rumi-
nants [7, 8, 14–17]. Ruminants instead have terminal ductal units
(TDU) which direct the elongation and branching of the ducts
during puberty and resemble a multi-lobular TEB, with each
ductule growing from a central chord of epithelial cells typically
4–5 cells thick [18]. Due to the general lack of availability of
human pubertal tissue the majority of work on TEBs has been
done in rodents. However, a number of tissue samples from teen-
age women indicate TEB structures that are similar to those of
rodents [19, 20]. Across species, TEBs are described as bulbous,
highly proliferative, hormone dependent, structures that appear
on the ends of growing ducts. The focus of this review describes
the knowledge gained from the collective work done in mice.
Terminal End Bud Biology
The terminal end bud (TEB) is a structure unique to the peri-
pubertal mammary gland [8]. At the onset of puberty, the TEBs
emerge from the stratified epithelium of the immature gland.
Multiple vertical apical divisions of the luminal layer are re-
sponsible for the stratification of the simple bilayer into a bul-
bous TEB structure [21]. The TEBs invade through the fat pad
and undergo regular bifurcation events to give rise to the pri-
mary mammary ductal tree (Fig. 2). Once the TEB reaches the
edges of the fat pad, the TEBs regress completely [22], leaving
behind blunt-ended ductal termini or sometimes smaller round-
ed buds which are frequently mistaken for TEBs but do not
exhibit the histological structure or high levels of proliferation
indicative of active TEBs. The TEBs are of special interest due
to their unique characteristics including a heterogeneous cellu-
lar composition, high proliferation (60–90%) and apoptosis
rates (5–15%), invasive ability, angiogenic properties, and their
ability to recruit stromal cells [23].
Structure
In the mouse, as in other mammals, the TEB is shaped gener-
ally like a light bulb, with the least differentiated and most
proliferative cells located in the bulbous region, and the more
differentiated, less proliferative cells in the neck and subtending
duct (Fig. 2). The TEB is made up of two main compartments.
The outer compartment is composed of a single-cell layer of
Bcap cells^ at the growing tip of the TEB, which differentiate
into myoepithelial cells as the duct elongates (Figs. 2 and 3). In
the mouse, the inner compartment is a multi-cellular layer ap-
proximately 4–6 cells in thickness known as the Bbody cell^
layer [8]. The body cell layer is thought to bemade up primarily
of luminal and alveolar progenitors whose progeny differentiate
into more mature luminal cells as the duct elongates (Fig. 3).
The cells within the TEB are held together loosely with two
types of cadherin-mediated adherens junctions. The body cells
express E-cadherin, whereas the cap cell layer expresses P-
cadherin [24], allowing these two compartments to act in a
coordinated fashion but also independently. E-cadherin appears
to be required for participation in ductal elongation, as cells
lacking E-cadherin expression are excluded from developing
Fig. 2 Terminal End BudWholeMounts and Histology. During puberty,
terminal end buds direct the growth of the duct through the fat pad and are
seen at the leading edge of the growing duct (top panel). The terminal end
buds are bulb shaped structures that undergo regular bifurcation events
(middle panel). A histological section of a terminal end bud reveals two
compartments that can be distinguished by expression of cell surface
markers (bottom panel)
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glands [25, 26]. P-cadherin, counterintuitively, is required to
maintain the organization of the body cell layer, as treatment
of TEBs with function-blocking antibodies against P-cadherin
cause body cells to disaggregate and fill the luminal space [24].
The interior body cells also contain desmosomes, which may
function in the process of collective migration during ductal
elongation [27, 28]. In the mature duct, the adhesion between
luminal cells becomes much stronger with the addition of tight
junctions and gap junctions, and myoepithelial cells adhere to
the basement membrane through hemidesmosomes [25].
The light bulb shape of the TEB is due, in part, to con-
straints provided by the extracellular matrix (ECM). The TEB
has a distinct ECM composition from the subtending and ma-
ture duct. While the bulbous tip of the TEB has a very thin
basement membrane (~104 nm) made up primarily of laminin
and collagen type IV, the basement membrane in the neck
region of the TEB becomes a thicker (~1.4um), more defined
meshwork that includes fibrillar collagen type IV, heparin sul-
fate proteoglycans, laminins 1 and 5 as well as fibronectin and
vitronectin [29–32]. The basal layer of the TEB and mature
duct is in direct contact with these ECM components.
Cap Cells
Cap cells are located around the leading tip of the TEB (Fig. 3)
and are thought to be a reservoir for regenerative mammary
stem cells as they have a higher ability to form an entire ductal
tree when transplanted as a purified population [33]. Cap cells
primarily give rise to the myoepithelial cells enveloping the
mature duct, but have also been hypothesized to contribute to
the luminal lineage as they have been observed migrating into
the body cell layer [8, 34]. Cap cells express several markers
that can be used to identify them, along with their mature coun-
terpart, myoepithelial cells. Some markers of the basal lineage
include keratin 5 and 14, smooth muscle actin, and p63 (Fig. 2).
Additionally, expression of a stem cell specific isoform of SH2-
containing inositol 5′-phosphatase (sSHIP) appears to mark cap
cells specifically, although the specific function of this isoform
in the mammary gland is unknown [33].
Body Cells
Body cells form the inner mass of the TEB and are thought to
include ductal and alveolar progenitors (Fig. 3). The inner most
cells are incompletely polarized while body cells adjacent to the
basal layer are polarized and form cadherin-based adherens
junctions, cells in the interior are loosely held together with
desmosomes [28]. The body cell layer gives rise to the luminal
cells lining the interior of the duct, and a subset are responsible
for differentiating into alveoli during pregnancy and lactation
[35, 36]. These cells express keratin 6, 8 (Fig. 2), and 18, and,
although they are not competent to respond to ovarian hormones
to form alveolar structures, a fraction of them do express the
estrogen and progesterone receptors [37, 38]. The body cell
layer has a high apoptotic index, which has historically been
understood as the major mechanism of lumen formation [39].
However, we recently discovered that the majority of the apo-
ptotic cells are of cap cell origin [40]. Thus, it remains unclear
what effect this pattern of apoptosis has on lumen formation.
Caps Cells as Potential Mammary Stem Cells
Due to the impressive regenerative capacity of the mammary
gland, the presence of a resident stem cell population has long
Fig. 3 Terminal End Bud. The
terminal end bud is a bulbous
structure made up of two main
compartments known as the cap
and body cell layers. The cells in
the front of the terminal end bud
(pink) are least differentiated (cap
cells and body cells), whereas cells
become more differentiated in the
narrowing region (myoepithelial
progenitors-green) and the neck of
the terminal end bud (luminal
cells- blue, mature myoepithelial
cells-green). Some cap cells can be
found in the body cell layer
(beige). The extra-cellular matrix
is light around the leading tip of
the terminal end bud and becomes
a complex meshwork in the neck
of the terminal end bud. Apoptosis
in the body cell layer contributes to
lumen formation (faded blue and
beige)
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been acknowledged [41]. DeOme et al. functionally demonstrat-
ed the existence of this cell type with transplantation assays, in
which they demonstrated that epithelial segments taken from
anywhere in the mature gland were capable of recapitulating
the entire functional gland when transplanted into a cleared fat
pad [42]. Additionally, in a series of studies using limiting dilu-
tion transplantation of retrovirally-tagged mammary epithelial
cells into virgin and pregnant females, it was demonstrated that
a single cell was capable of re-growing the entire mammary
gland, and that lineage restricted progenitors for alveolar out-
growths and ductal branching were also present in the mature
duct [43–45]. It has been postulated that cap cells are examples
ofmultipotent mammary stem cells based on observationsmade
during time lapse videos and several studies acknowledging the
presence of cells of basal lineage within the body cell layer [8,
46–48]. More recently, cap cells have been shown by limiting
dilution transplantation to produce a full mammary gland more
frequently than other basal lineage cells when transplanted [33].
However, transplantation of single cells may not faithfully reca-
pitulate the function of cells in the intact gland and recent line-
age tracing in vivo has led to contrary conclusions regarding the
stemness of cap cells [34, 49]. Van Keumeulen et al. [49] first
published lineage tracing data using K14, K8, and K18 pro-
moters to label different cell populations during mammary de-
velopment. They determined that an embryonic K14-Cre/Rosa-
YFP labeled stem cell gives rise to all mammary epithelium,
while in puberty these K14-rtTA/TetO-Cre/Rosa-YFP labeled
cells mark a lineage restricted progenitor cell that gives rise only
to myoepithelium. A second lineage tracing study by Rios et al.
[34] used a confetti reporter under a bovine K5 promoter and
showed that induction during puberty resulted in labeling of
both cap and body cells in the terminal end bud. This induction
also resulted in clonal populations containing both lineages after
an 8 week chase, suggesting the existence of a population of
bipotent cells in the TEB during ductal elongation.
Interestingly, the cap cell population also exhibits high
levels of Wnt signaling, which is regarded as a hallmark of
stemness in many tissues [50] and expression of Par3L, a
regulator of polarity essential for maintenance of stemness in
the mammary gland [51]. In contrast to these data, recent
studies investigating the fate of cap cells that have migrated
into the body cell layer indicates that these cap cells are un-
dergoing apoptosis and are not contributing to both basal and
luminal lineages [40]. Together these data concerning a bi-
potent stem cell in the TEB during ductal elongation remain
contradictory and warrant further specific study.
Mammary Stroma and TEB Function
The mammary stroma, as a whole, is important for proper
ductal morphology, and has been shown to be instructive for
ductal morphogenesis. For example, mammary epithelium,
transplanted into salivary mesenchyme, takes on the morphol-
ogy of the salivary gland, although the cells maintain a mam-
mary cell identity, as demonstrated by the production of milk
proteins upon stimulation with pregnancy hormones [52]. The
stroma from mice at different stages of the reproductive cycle
also promote different aspects of duct development: stroma
from virgin animals promotes branching and elongation, stro-
ma from pregnant mice promotes alveolar differentiation, and
stroma from involuting glands promotes epithelial apoptosis
[52]. Therefore, the mammary stroma itself plays a role in
ductal elongation and branching morphogenesis.
Additionally, the mammary stroma is made up of several cell
types including adipocytes, fibroblasts, macrophages, eosino-
phils, neutrophils, and endothelial cells. The TEB uniquely
comes into direct contact with these cells in the stroma at its
leading tip. Several stromal cell types, including fibroblasts,
macrophages and eosinophils, are all localized around the
TEB during ductal elongation (Fig. 4) [53–56].
Fibroblasts
Fibroblasts are localized around the TEB and are responsible
for the production of local growth factors, including fibroblast
growth factors (FGFs), insulin-like growth factor-1 (IGF-1)
and hepatocyte growth factor (HGF) when activated by sys-
temic estrogen and growth hormones [56–58]. Growth factor
signaling to the epithelium promotes the expansion of the
luminal compartment during ductal elongation [53].
Fibroblasts also facilitate ECM production and degradation
by producing laminin, collagen, fibronectin, proteoglycans,
matrix metalloproteinases (MMPs), and tissue inhibitors of
metalloproteinases (TIMPs) (Fig. 4) [56].
Macrophages
Macrophages are localized to the TEB during ductal elonga-
tion. The macrophages are found around the neck of the TEB
where they are recruited by the production of colony stimulat-
ing factor 1 (CSF1) by epithelial cells. Macrophages are also
found within the body cell layer, where they contribute to
lumen formation by clearing apoptotic cells via phagocytosis
(Fig. 4) [55]. Depletion of the macrophage population results
in decreased ductal outgrowth, branching, and TEB number,
as well as changes in TEBmorphology to a more rounded and
blunt shape [54]. In the stroma, the macrophages localize
mostly to collagen fibers and are thought to play an important
role not only in the production of collagen I, but in its remod-
eling into long fibrillar bundles that project from the sides of
the TEB in the direction of forward growth (Fig. 4) [54].
Macrophages are also involved in EGF signaling in the devel-
oping mammary gland which is discussed further below.
J Mammary Gland Biol Neoplasia
Eosinophils
Eosinophils are found specifically around the leading tip of
the TEB where they are recruited by the secretion of eotaxin
by the TEB (Fig. 4) [55, 56]. Recently it has also been dem-
onstrated that progesterone and estrogen induced
amphiregulin (Areg) expression is sufficient to recruit eosin-
ophils in ovariectomized mice [59]. Failure to recruit eosino-
phils to the TEB results in a decrease in branch number and
TEB formation [55]. Interestingly, ductal elongation is not
defective without eosinophils, indicating that the eosinophils
may be more important for branch patterning than ductal elon-
gation itself [55, 56]. Eosinophils are known to produce cyto-
kines and growth factors including VEGF, although their ex-
act function in the mammary gland is unknown [60].
Signaling and TEB Function
Systemic signals required for proper morphology at each stage
of mammary gland development has been well studied [61].
However, signaling within the TEB specifically, is still an area
of ongoing investigation. While some factors are required for
mammary gland development in general or at other stages, a
few factors such as estrogen, FGF10, and GH are required for
TEB formation, and other signaling molecules such as Wnt,
SLIT, and TGFβ have subtle and sometimes divergent roles in
TEB morphology and function.
Estrogen
Estrogen, primarily from the ovary, can be secreted into the
blood stream to act systemically on distant organs. Estrogen
can also be synthesized locally in the mammary gland by
adipose tissue and the enzyme aromatase [62]. In classical
nuclear signaling, estrogen can bind its main receptor, estro-
gen receptor alpha (ESR1), causing dimerization and translo-
cation into the nucleus, where it affects gene transcription.
There is growing evidence for non-nuclear actions of ER at
the plasma membrane as well [63, 64].
Estrogen activity is important for sustained proliferation dur-
ing ductal elongation and acts directly on the epithelium via ERα
[65, 66]. Estrogen binds its receptor in a subset of luminal cells,
which are then responsible for the production of amphiregulin
(Areg). Areg is expressed as a transmembrane precursor that
requires cleavage by ADAM17 in order to signal to nearby
stromal cells. Areg signals in a paracrine manner to the stroma
where it binds its receptor, epidermal growth factor receptor
(EGFR), and causes additional expression of growth factors,
including fibroblast growth factor (FGF) (Fig. 5a) [67]. Ectopic
expression of Areg can rescue outgrowth in ERKO mice [68,
69]. Estrogen signaling alone can induce formation of some
TEBs but estrogen in conjunction with growth hormone has a
synergistic effect to form many TEBs [57]. While there are also
activities of estrogen in the mammary stroma, as demonstrated
by tissue recombination experiments and disruption of the ESR1
gene, these are not essential for ductal growth [70] .
Fig. 4 Stromal Cell Types
Involved in Ductal Elongation.
The mammary stroma contains
many cell types that together are
instructive for ductal
morphogenesis. Three cell types
are localized around active
terminal end buds and are
important for ductal elongation.
Fibroblasts (blue) are found
around the advancing tip of the
terminal end bud and produce
extracellular matrix proteins and
growth factors. Macrophages
(green) are found at the neck of
the terminal end bud where they
organize extracellular matrix
proteins into a complex
meshwork. Macrophages are also
found within the body cell layer
where they help to remove
apoptotic bodies. Eosinophils
(purple) are recruited to terminal
end buds by eotaxin and are
important for branching. The
stroma also contains adipocytes
(beige)
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Progesterone
Progesterone (P4) is produced in the ovary by the granulosa
and thecal cells in the corpus luteum. Once secreted, P4 can
bind its receptor (PR) and regulate transcription of PR target
genes [71], namely receptor activator of nuclear factor kappa
B ligand (RANKL)which acts in a paracrine manner to induce
proliferation and secretory fate in nearby PR- cells [72]. The
progesterone receptor has two isioforms, PRA and PRB, al-
though only PRB is required in the mammary gland [61].
The role of progesterone signaling in pubertal outgrowth is
controversial. Several early studies indicated that PR is
dispensible for ductal elongation but required for side
branching and alveolar budding in the adult animal [73–75].
More recent work with IGF-1 KO mice treated with IGF-1
and estrogen or progesterone has demonstrated that PR sig-
naling has a synergistic effect on ductal outgrowth, similar to
that of estrogen [76]. In addition, reciprocal transplantation
experiments indicate divergent roles for PR in the epithelium
vs the stroma, with stromal PR being important for ductal
outgrowth but not alveolar budding and epithelial PR being
disspensible for ductal outgrowth but required for alveolar
budding [77, 78]. Most recently, Aupperlee et al. [79] dem-
onstrated that progesterone, although not required for ductal
elongation, is sufficient to cause TEB formation and ductal
outgrowth in ovariectomized mice. Authors claim is this
probably due to overlapping regulation of Areg by both PR
and ER [79].
Fig. 5 Signaling Essential for Terminal End Buds. a Estrogen from the
ovaries signals through the Estrogen Receptor positive luminal cells to
produce the paracrine factor amphiregulin, which acts on stromal cells to
produce additional growth factors. b Growth hormone from the pituitary
acts on fibroblasts near the terminal end bud to produce insulin growth
factor which promotes proliferation in the epithelial cells. c The
adipocytes produce fibroblast growth factor 10 which acts specifically
on basal cells to induce a pro-proliferative response in the luminal
compartment. d Transforming Growth Factor Beta is produced by the
epithelial cells and secreted as a latent complex. Once cleaved it has
divergent effects on stromal and epithelial cell types. e Canonical and
non-canonical Wnt signaling oppose each other to control stemness in
the mammary gland during puberty. f SLIT2 is produced by both luminal
and basal cells in the terminal end bud and binds to the ROBO receptor
found only in the basal compartment to promote survival of cap cells
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Growth Hormone
Growth Hormone (GH) is important at the onset of puberty to
induce formation of TEBs. GH is produced by the pituitary
and released into the blood stream in response to signaling
from the hypothalamus, but GH can also be produced in the
ovary [80].
GH promotes the formation of TEBs by acting primarily in
the stroma via paracrine IGF-I signaling. The downstream
effector of GH signaling, IGF-I, is required for TEB forma-
tion, and treatment of mice with GH or IGF-I alone will form a
limited number of TEBs (Fig. 5b). However, the addition of
estrogen signaling causes bursts of proliferation that is re-
quired for rapid ductal production during puberty [65, 70,
81–83]. After the formation of TEBs, IGF-1 is expressed in
the stroma and within the TEB and is important for proper
branching pattern but is not necessary for maintenance of the
TEB itself [84].
Epidermal Growth Factor Family
The epidermal growth factor receptor (EGFR) is a receptor
tyrosine kinase (RTK). Binding of EGF to its receptor results
in receptor dimerization and activation of the intracellular ki-
nase domain with subsequent trans-auto phosphorylation.
Downstream signaling includes wide ranging effects. EGFR
activation of Ras/MEK leads to mitogenic signals; activation
of PLC-γ1 regulates migration; and activation of PI3K-AKT
leads to cell survival [85]. EGF family ligands are expressed
as transmembrane precursors that require cleavage for recep-
tor binding and activation. In the mammary gland ADAM and
MMPs are responsible for EGF ligand cleavage [86, 87].
Both EGF and EGFR are expressed in the mammary gland
during puberty, alveolar differentiation, and lactation [88].
During puberty, EGFR is highly expressed in the TEBs and
the surrounding stroma [89]. Implantation of an EGF-
containing pellet into growth quiescent glands of ovariecto-
mized mice resulted in TEB formation and local outgrowth,
however implantation of pellets into mice with intact ovaries
did not result in increased growth [89]. Reciprocal transplan-
tation studies of epithelium and stroma expressing a kinase-
impaired form of EGFR (waved-2) determined that EGF sig-
naling in the stroma is important for successful ductal out-
growth during puberty [90]. Further, expression of a dominant
negative EGFR also caused decreased outgrowth and glands
failed to form TEBs all together. However, upon pregnancy
these animals successfully underwent alveologenesis and lac-
tation suggesting a pregnancy associated rescue of the ductal
outgrowth [91].
ErbB2 is highly expressed in the mammary epithelium
during puberty. This receptor is best known for is proto-
oncogene role in breast cancer, however, it also plays an im-
portant role in normal mammary gland development. ErbB3 is
not capable of kinase activity and therefore requires hetero-
dimerization with another receptor for downstream signaling.
ErbB2 is thought to be its main partner in signaling due to
their co-expression in breast cancers and because KO of Erbb4
has no effect on outgrowth during puberty [92]. Both ErbB2
and ErbB3, on the other hand, seem to be important for ductal
elongation and TEB regulation. Both ErbB2 and ErbB3 KO
mice die in utero, however when mammary buds were
transplanted into WT animals Jackson-Fisher et al. found that
the two receptors share a similar phenotype [93]. ErbB2 −/−
and ErbB3−/− epithelium were both unable to fully fill the fat
pad compared to the contralateral WT controls. Interestingly,
ErbB3-null glands contained more TEBs (and more
branchpoints), however they were of smaller size than WT
controls, and regress by 20 weeks even without filling of the
fat pad. Further, the TEBs of both KOs exhibit aberrant orga-
nization including multilayered cap cell regions, increased
number of cap cells in the body cell layer, large gaps between
the cap and body cell layers, and luminal filling [93]. Together
these data are strong support for the cooperative signaling of
ErbB3 and ErbB2 in the TEB during ductal elongation.
Fibroblast Growth Factor
There are 23 FGF ligand family members but only a subset
have been investigated in the mammary gland with FGFR
signaling being required for normal development ([94, 95]
and references therein). Canonical FGF subfamily members
signal in a paracrine manner from mesenchymal cell types to
epithelial cells. Successful ligand binding results in phosphor-
ylation of the intracellular tyrosine domains on FGFR, which
in turn activates downstream signaling including Ras-MAPK
and PI3K-Akt pathways, resulting in mitogenic and prolifer-
ative responses within the cell.
During ductal elongation, FGF1, FGF2, FGF4, FGF7 and
FGF10 are all highly expressed in the mammary gland [94].
Overexpression of Fgf4 under control of the WAP promoter
inhibits ductal elongation and side branching in conjunction
with causing structural defects in the TEB including large
lumen, a lack of a neck region and cap cell layer, and layers
of cells filling the lumenal space. These TEBs also exhibit
decreased level of apoptosis [96]. Fgf7 also seems to play an
inhibitory role in branching possibly through opposition to
TGFalpha signaling [97].
The best characterized FGF ligand-receptor pair is FGF10/
FGFR2b. Fgf10 is produced by the adipose tissue and acts in a
paracrine manner on the mammary epithelium. Fgf10 ligand
is localized in the mesenchyme near ducts and alveoli, while
its receptor Fgfr2b is localized to the TEB (Fig. 5c) [98].
Fgf10 binds Fgfr2b in a specific manner with heparan sulfate
as a required cofactor [99]. Conditional knock out (KO) of
FGFR2b in the mammary epithelium immediately following
birth and continuing into the first few weeks of puberty results
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in failure to form TEBs or to grow past the lymph node [95].
This is due to a large decrease in proliferation in the luminal
epithelium specifically and an increase in apoptosis. This
seems to be only a temporary block, as withdrawal of doxy-
cycline results in formation of TEBs and successful out-
growth, indicating that FGF10 signaling is not required to
maintain the regenerative ability of the mammary epithelium
[100]. Further studies have shown that Fgfr2 is required in the
basal compartment for regeneration of a gland after transplan-
tation, and that basal cells lacking Fgfr2 fail to give rise to
luminal progeny [95]. Interestingly, in vitro work has indicat-
ed that Fgf10 from a point source acts as a chemoattractant for
MECs and may provide a directional cue for TEB growth
in vivo [53].
Transforming Growth Factor Beta
Transforming Growth Factor Beta (TGFβ1, TGFβ2, TGFβ3)
ligands are secreted as a latent complex that is activated by
cleavage by proteases including MMP-9, thrombospondin, or
plasmin [101]. Therefore they are often found in the extracel-
lular matrix, which acts as a reservoir. When activated, the
ligand binds its receptor, TGFβRII and TGFβRI, which re-
sults in internal kinase activity and the activation of SMAD
dependent and independent signaling cascades. Eventually,
this activation results in various downstream actions including
gene transcription, motility, invasion, apoptosis, proliferation,
and ECM remodeling. The final physiological response to
TGFβ signaling depends on the expression of other transcrip-
tion factors and signaling proteins that work in conjunction
with SMAD proteins.
In the mammary gland, TGFβ isoforms are expressed in
the epithelium at all phases of development and generally act
as inhibitors of proliferation and promoters of ECM deposi-
tion [102]. TGFβ1 and TGFβ3 have overlapping expression
patterns in the epithelium during ductal elongation, although
TGFβ3 is the only isoform found within the cap cell layer of
the TEB. TGFβ2 is expressed at very low levels in the TEB
and is upregulated during pregnancy. Initially, TGFβ ligands
were shown to inhibit the growth of TEBs when ectopically
expressed [103, 104]; however, it has since been shown that the
levels of TGFβ have divergent affects. Low levels
(femtomolar) of TGFβ stimulate branching morphogenesis ,
and higher levels (picomolar) inhibit growth [105].
Interestingly, TGFβ signaling in stromal cells induces prolifer-
ation and production of ECM (Fig. 5d) to contribute to TEB
regression [106]. High estrogen levels during puberty inhibit
TGFβ ligand expression, resulting in low TGFβ levels during
ductal elongation. Overexpression of an activated form of
TGFβ1 during ductal elongation results in hypoplastic growth
[107], whereas glands from TGFβ1 heterozygotes have a two-
fold increase in ductal elongation and proliferationwithin TEBs
[108]. Additionally, deletion of TGFβ1 in mouse epithelium
resulted in aneuploidy, centrosome aberrations, and impaired
DNA damage response (DDR) through crosstalk between
SMADs and ataxia telangiectasia mutated (ATM), a protein
kinase that is activated by DNA double-strand breaks. This
aspect of TGFβ function is especially interesting in a breast
cancer context, in which TGFβ-resistant cells may be under
positive selection. This role of TGFβ has not been explored
in the TEB, although maintenance of DDRwould be especial-
ly important in such a highly proliferative structure [109].
WNT
There are 19 identified Wnt ligands and 10 Frizzled receptors
as well as several co-receptors [110], which have been the
subject of intensive research in the mammary gland for over
two decades ([111] and references therein). The Wnt pathway
can be activated by both canonical and non-canonical ligands.
In the canonical pathway, Wnt ligands bind to a Frizzled re-
ceptor and a low-density lipoprotein receptor-related protein 5
or 6 (LRP). This association causes the disassembly of a
multiprotein complex containing glycogen synthase kinase 3
(GSK3), casein kinase 1α (CK1), axin and adenomatous
polyposis coli (APC), and β-catenin; allowing the β-catenin
to translocate into the nucleus and bind LEF transcription
factors. The non-canonical pathway does not involve LRP
coreceptors or the stabilization of β-catenin, but rather can
result in changes in cell polarity and cytoskeletal rearrange-
ments through the planar cell polarity pathway (PCP) or result
in the release of intracellular calcium through the calcium
pathway. The PCP pathway results in downstream activation
of disheveled, JNK and Rho family GTPases, which direct
asymmetrical cytoskeletal rearrangements and cellular polari-
ty. In the calcium pathway, Frizzled acts through G-proteins to
activate phospholipase C (PLC) which results in release of
intracellular calcium and eventual activation of the transcrip-
tion factor NFAT [112]. Additionally, the non-canonical path-
ways can signal through alternate Ror and Ryk receptors.
Wnt pathway components are temporally and spatially dif-
ferentially expressed in the mammary gland [113, 114]. For
instance, the LRP6 co-receptor is expressed in both layers of
the epithelium and stroma during embryogenesis; however, in
the juvenile and adult, expression in the epithelial compart-
ment localizes to the basal layer only [115]. Further, ligands
Wnt4 and Wnt5a are localized to the luminal compartment,
whereasWnt6 is localized to the basal layer. The cognate non-
canonical receptors for these ligands follow similar patterns of
expression [50].
Canonical Wnt signaling is required for stem cell mainte-
nance, branching, and alveologenesis in the mammary gland.
Canonical signaling has been shown to be important in TEBs
because Lrg5 and 6 are required for canonical signaling and
are localized to the basal layer (Fig. 5e). With targeted deletion
in mammary glands, fewer TEBs develop and glands have
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diminished side branching [115, 116]. The LRP5 co-receptor
is also important in the luminal layer for stem cell function and
regenerative ability during transplantation [117]. Similarly,
Wnt4, has been shown to act through the canonical pathway
specifically in the myoepithelial cells starting in the neck of
the TEB. Canonical signaling was also seen in the TEB and
the stroma directly surrounding the TEB but was not Wnt4
dependent [118].
Non-canonical Wnt signaling also plays an important role in
the developing mammary gland. In situ hybridization has
shown the specific expression of Wnt2, Wnt5a, and Wnt7b in
the TEB during puberty. Wnt5a, a non-canonical Wnt ligand,
regulates branching and proliferation within the TEB by
inhibiting Wnt/β-Catenin activity [119]. Interestingly, the
non-canonical receptor Ror2 has been shown to be important
for normal TEB morphology and for controlling proliferation.
Ror2 expression shows an inverse relationship to Wnt activity
in the TEB,where Ror2 is expressed in the neck and subtending
duct and β-catenin activity occurs in the cap cell layer of the
TEB. Knockout of Ror2 results in increased branching during
outgrowth, decreased percent fat pad filled, and budding in the
neck of the dysmorphic TEBs. Roarty et al., concluded that
Wnt/β-catenin activity and Ror2 expression oppose each other
in the TEB to maintain stemness in progenitor populations in
the cap cell region, inhibit proliferation in committed cells in
the neck of the TEB, and promote differentiation of the
myoepithelial cell type throughout the TEB (Fig. 5e).
Other Wnt ligands and receptors remain unstudied in
mammary gland development, and further detailed stud-
ies are needed to fully understand this complex signaling axis
in the TEB.
Axon Guidance Molecules
There are many other signaling molecules being explored as
potentially important for mammary gland development. These
include SLIT/ROBO and Netrin1/Neogenin. These molecules
are members of the axon guidance genes most well known for
their role in axonal growth and migration. More recently it has
become clear that they play important roles in tissue morpho-
genesis in diverse organ types including the mammary gland.
SLIT2 is expressed in both the body cell and cap cell layer
of the TEB; however, its receptor, ROBO1, is expressed ex-
clusively in the cap cell layer (Fig. 5f). In both SLIT2 and
ROBO KO studies TEBs show severe abnormalities, includ-
ing separation of the cap and body cell layers, invagination of
the cap cell layer, and disorganization of the body cell layer.
Interestingly, Netrin1/Neogenin KO mice have nearly identi-
cal phenotypes [120]. Netrin1 KOmice do not exhibit cap cell
invaginations, although they do exhibit an increase in the
number of cap cells present in the body cell layer, and an
increase in overall cap cell death. Further studies of the
Slit2/ROBO1 pathway have determined that Slit2 regulates
the expression of Inscuteable (mInsc), which is responsible
for regulation of asymmetric versus symmetric cell division
in the cap cell layer. Ballard et al. showed that increased levels
of mInsc causes increased outgrowth during puberty due to an
expansion of the stem cell compartment presumably via an
increase in symmetrical divisions, however these mice did
not exhibit any morphological changes in the resulting out-
growths as one would expect from an expansion of the stem
cell compartment [121].
Other genes involved in axonal guidance are known to be
expressed or enriched in the TEB, including brain acid-soluble
protein 1 (BASP), small proline rich protein 1A (sprr1A), and
semaphorin 3B [122]. However, they have not been function-
ally or specifically studied during puberty. Further work in this
area promises to uncover interesting details in TEB biology.
Mechanisms of Forward Growth
The exact mechanism of TEB forwardmovement has not been
completely elucidated. One theory is that mechanical pressure
from ECM production and stromal condensation in the neck
of the TEB in conjunction with high proliferation rates within
the body cell layer combine to cause net forward movement.
In vitro studies have recently indicated that a collective migra-
tion mechanism may also be important for TEB forward prog-
ress, and of course matrix degrading proteins secreted by the
TEB itself are thought to be important for creating a path of
least resistance. Together, these characteristics make the TEB
a unique structure in organogenesis, which may provide valu-
able insight into the understanding of other migratory and
invasive groups of cells including cancers.
1) Collective Migration
Collective migration is the process that enables the coordi-
nated movement of groups of cells that retain their cell-cell
junctions. Collective migration requires the coordination of
adhesion, polarization, and mechanocoupling to sense exter-
nal guidance cues that can then be transmitted throughout the
group of cells. It also involves the establishment of leader-
follower relationships, in addition to the chemical guidance
mechanisms seen in individual cell movement [123].
Studies by Ewald et al. have demonstrated a novel mecha-
nism by which mammary ducts elongate. While the TEB has
hallmarks of collective migration, a major distinction in the
TEB is the lack of subcellular protrusions at the leading edge.
TEBs instead have a completely smooth surface at the leading
edge, which makes this structure unique. Interestingly, cells in
the interior of the body cell layer exhibit characteristics of
active migration with both protrusions and active motility ob-
servable by live imaging [28].
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Ewald et al. also used an organoidmodel to study elongation
and branching in vitro. They found that mammary organoids go
through distinct stages of elongation. First, organoids form po-
larized bilayers with large clear lumens. Second, they undergo
luminal filling to form a complex cyst similar in morphology to
a TEB in vivo. Finally, organoids undergo proliferation-
dependent elongation. Elongating regions are always multilay-
ered with thinning and reversion to a simple bilayer at sites
adjacent to the elongating region—resembling the bulb mor-
phology of a TEB. Upon closer inspection, Ewald et al. ob-
served the chaoticmovement of both luminal andmyoepithelial
cells in the leading tip during elongation [27] [28]. The luminal
cells constantlymoved in a forward direction, but myoepithelial
cells moved in both forward and reverse directions.
In addition to the behaviors above, Ewald et al. also ob-
served bifurcation events that occurred only at areas with par-
tial coverage by myoepithelial cells, whereas complete cover-
age resulted in cessation of elongation [27]. Interestingly, un-
like previous descriptions of collective migration, the cells at
the advancing tip never exhibited cellular extensions or actin-
rich protrusions. Instead, the cells continuously exchanged
positions while maintaining a completely smooth edge [27].
Further studies using transmission electron microscopy
(TEM) confirmed the lack of even fine protrusions from the
basal layer into the ECM, as well as from the luminal layer
into the ECM. There were, however, complex interdigitations
between body cells in the interior of the organoids and within
TEBs in vivo. These extensive cell membrane structures are
both simple and branched in different areas and contain des-
mosome attachments between neighboring cells [27, 28].
It is interesting to note that the complex interdigitation seen
in the body cell layer of the TEB is similar to the morphology
of atypical ductal hyperplasias, intraductal carcinomas, and
infiltrating ductal carcinomas [28, 124], providing an addi-
tional link between characteristics of the TEB and those of
invasive breast tumors. The TEB may therefore be a useful
model for the specific study of these interdigitations, and their
role in cell communication, invasion, and mobility, particular-
ly as these functions relate to breast cancer.
2) Epithelial to Mesenchymal Transition
Epithelial to mesenchymal transition (EMT) is a normal
process involved in embryogenesis and organogenesis in
which polarized epithelial cells undergo biochemical changes
to assume a mesenchymal cell phenotype. There are three
classifications of EMT; type 1 includes normal changes during
implantation and organogenesis, and does not result in inva-
sive phenotypes; type 2 is associated with wound healing and
regeneration and results in fibrosis and inflammation; and type
3, which is reserved for neoplastic cells and results in invasion
and metastasis of the primary tumor. Many signaling path-
ways involved in the regulation of EMT regulation are also
present in the TEB includingWnt, FGF,TGFβ [125], Slug and
Snail [126].
Motile cells within the TEB seem to have undergone a par-
tial EMT due to reduced polarity, reduced adhesion, and in-
creased motility characteristics. Indeed, the cells within the
body cell layer only contain desmosomal adhesions, but inter-
estingly, these seem to play an inhibitory role in ductal elonga-
tion since chemical inhibition of desmosomal proteins causes
increased branching [127]. Additionally, cells within the TEB
express markers of EMT including Slug, Zeb1, and Twist
[128]. The increased mobility endowed by the EMT in body
cells may provide additional support for the forward movement
and invasion of the fat pad during ductal elongation.
3) Matrix Metalloproteinases and Heparanase Production
The TEB expresses several proteins that aid in forward
movement. The cap cell layer expresses MMPs and heparanase
[129], which selectively degrade the ECM immediately in front
of the TEB in order to create a path of least resistance, possibly
to aid in forward movement. It has recently been shown that
MMP-14 and heparanase form a reciprocal positive feedback
loop in the TEB that increases branching. Gomes et al., showed
that knock down of heparanase in vivo and in vitro results in
decreased branching during ductal outgrowth concomitant with
a decrease in MMP-14 levels, and vice versa [129]. Further,
work by the same group has shown through selective domain
deletion studies that MMP-14 has a non-proteolytic role in
branching morphogenesis through binding to integrin β1 and
activating the MAPK signaling pathway. They also presented
evidence that MMP-14, integrin β1, and MAPK pathway acti-
vation form a three-way regulatory loop. Together, these data
indicate a complex interaction between MMP-14, integrin,
heparanase, and the MAPK pathway activation that is essential
for successful TEB invasion and ductal elongation [130].
A downstream target of MMP-14, MMP-2, is also involved
in ductal outgrowth during puberty. Although TEBs have a nor-
mal morphology, size, proliferation rate, and basement mem-
brane composition, MMP-2 KO mice have a greatly increased
number of apoptotic cells, which is thought to inhibit the ability
of these TEBs to invade the fat pad by mitigating the forward
pressure from proliferation [131]. MMP-11 KO mice exhibit a
similar phenotype to MMP-2 KO mice in that they exhibit de-
fective ductal outgrowth, with ducts never filling the fat pad,
whereas the morphology of the TEBs is normal. Together these
data indicate a role forMMPs in the ability of TEBs to invade the
fat pad, but not necessary for proper TEB morphology [130].
4) Basement Membrane Deposition
The cap and myoepithelial cells deposit the basement
membrane during ductal elongation, which results in both
polarization of the luminal layer and geometric confinement
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of the subtending duct. Laminin-1 expressed by the
myoepithelial cells [8, 29] has been shown to be required for
proper polarization of luminal cells in culture, the absence of
which contributes to disorganization in breast cancers [132].
The tip of the TEB is covered in hyaluronic acid and laminin;
however, starting in the neck of the TEB, the basement mem-
brane becomes a thick meshwork of collagen type IV, laminin
1 and 5, and heparin sulfate proteoglycans [30]. Fibroblasts,
adipocytes, endothelial cells and immune cells also contribute
to the production of ECM [133]. Not only the composition of
the ECM but also its orientation seems to be important for
ductal morphogenesis as collagen fibers radiate out from the
TEB and ductal development follows topographical cues in
the ECM [54, 134, 135].
In vitro studies have also indicated that mammary acini
rotate constantly in space as laminin is deposited, and that this
rotation is dependent on both correct polarization of the cells
and deposition of laminin-1 and collagen IV [136]. Whether
this rotation aids in forward movement during ductal elonga-
tion has not been verified, but it is possible that TEBs move in
a corkscrew type manner in order to better invade the stroma.
Terminal End Buds as Models for Cancer
Although the TEB is a normal structure and behaves in an
organized manner, many of the biological processes involved
in its growth are also required for the abnormal growth of
tumors. As such, the TEB can be used as model for the study
of several aspects of breast cancer biology (Fig. 6). First, like
breast cancers, TEBs have extremely high proliferation and
apoptosis rates and a heterogeneous cell population [34, 49,
137], comparable to breast tumors [138–140]. Second, the
TEB recruits its own blood supply as it grows through the
nascent fat pad, causing blood vessels to form around the
ducts [59]. This is most likely through the recruitment of mac-
rophages, which in turn, recruit endothelial cells, but also
through the epithelial expression of vascular endothelial
growth factor (VEGF) [141]. Tumors are known to also recruit
blood vessels that aid in their continued growth through the
overexpression of VEGF [142, 143]. Third, the TEB is an
invasive structure, with a unique basement membrane
composition and thickness, which allows for specialized
interaction with the mammary stroma. During tumor in-
vasion, factors that are expressed normally in the TEB,
such as MMPs, are dysregulated to degrade the base-
ment membrane and facilitate invasion and interaction
with the stromal cell types directly [144]. Finally, a
relatively unstudied commonality between TEBs and ab-
normal growths are micro-scale cellular inter-digitations
unique to body cells and hyperplasias [27, 124], the
functions of which remain unclear.
The TEB is alsomore highly susceptible to early oncogenic
insult resulting in tumors later in life. Studies in rats indicated
that glands exposed to 7,12-dimethylbenz(α)anthracene
(DMBA) during puberty formed tumors at a higher rate than
rats exposed at older ages [14]. This is most likely due to the
high proliferation rate and accelerated cell cycle unique to the
TEB, in both rats andmice, whichmay compromise the ability
of repair machinery to work in these cells [15, 40]. It remains
unclear whether homologous recombination (HR) or non-
homologous end-joining (NHEJ) is the favored repair mech-
anism in the TEB although MaSCs have been shown to have
increased, error-prone, NHEJ activity [145].
One caveat to the use of the TEB as a model of cancer are
the apparent differences between the collective migration in-
vasion mechanism of the TEB and the single cell active mi-
gration exhibited by cells within DCIS as it transitions into
invasive breast cancer. However, with respect to what aspect
of tumor/TEB biology to study, whether the investigator is
interested in molecular signaling (MMPs, adherens junctions,
VEGF, etc.), epithelial-stromal interactions (fibroblasts, mac-
rophages), ECM composition and integrity, or gene expres-
sion, the TEB is an under-utilized model system.
Fig. 6 The Terminal End Bud as A Model for Breast Cancer. The
terminal end bud has many important features in common with early
breast cancers including close contact with specialized stromal cell
types, and several signaling pathways that are important for cell growth
and survival
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Conclusion
The TEB remains a powerful Bexperimental organism^ for the
study of developmental phenomena and may provide valuable
insight into cancer dynamics. Data indicate that the TEB rep-
resents a unique example of 3D collective migration. Not only
do the internal cells within the TEB exhibit active mi-
gration, but the combination of adhesion molecule ex-
pression (P- and N-cadherin), secretion of ECM remod-
eling factors (heparanase and MMP-14), and basement
membrane deposition provide key effects that together
lead to fat pad invasion. Further, the TEB represents a
unique environment for molecular signaling studies, as it re-
sponds to systemic factors, paracrine signals, and physical
signals from the ECM.
Several aspects of TEB biology remain undefined. One
aspect that still remains unclear is the role of topographical
instructive cues such as collagen tracks, which may help to
direct ductal elongation. Additionally, the regulation of the
transition from the bulbous form of the TEB into a simple
bilayer of the mature duct is not fully understood. While there
has been an effort to tease out the molecular signaling path-
ways involved in TEB formation, maintenance, and regres-
sion, there is still much work remaining in order to understand
the complex dynamics of this structure.
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